Last Patient/Last Visit completed on November 13th enabling full clinical database lock
Company founder David R. Elmaleh, Ph.D., remains Executive Chairman of the Board and Chief Scientific Officer
Proceeds will help AZTherapies expand regulatory and pre-commercial activities related to Phase 3 candidate for early Alzheimer’s disease and advance other neuroinflammation-targeted programs
Randomized, open-label, multi-center, dose optimization study expected to evaluate 80 patients with mild- to moderate-stage ALS
Additions enhance company’s access to expertise in neurodegenerative disease biology, immunology, and regulatory T-cell science
Noah Gottdiener and Thierry Porté join BOD; Joseph B. Kelley joins Business Advisory Board
One new drug may treat both Covid-19 and Alzheimer’s
The interview took place at the 2020 BIO CEO & Investor Conference
Jay Mohr, Chief Operating and Business Officer, will be providing a corporate update and participating on a late-stage CNS therapeutics panel.
Company will be providing a company overview and participating on a CNS panel
Anti-inflammatory drug cromolyn successfully delayed disease onset and was neuroprotective in a mouse model of ALS
Brings more than 20 years of experience in the life science industry to support pre-commercial and regulatory activities of Phase 3 candidate ALZT-OP1 for early Alzheimer’s disease
Last Patient/Last Visit completed on November 13th enabling full clinical database lock
Company founder David R. Elmaleh, Ph.D., remains Executive Chairman of the Board and Chief Scientific Officer
Proceeds will help AZTherapies expand regulatory and pre-commercial activities related to Phase 3 candidate for early Alzheimer’s disease and advance other neuroinflammation-targeted programs
Randomized, open-label, multi-center, dose optimization study expected to evaluate 80 patients with mild- to moderate-stage ALS
Additions enhance company’s access to expertise in neurodegenerative disease biology, immunology, and regulatory T-cell science
Noah Gottdiener and Thierry Porté join BOD; Joseph B. Kelley joins Business Advisory Board
One new drug may treat both Covid-19 and Alzheimer’s
The interview took place at the 2020 BIO CEO & Investor Conference
Company will be providing a company overview and participating on a CNS panel
Anti-inflammatory drug cromolyn successfully delayed disease onset and was neuroprotective in a mouse model of ALS
Brings more than 20 years of experience in the life science industry to support pre-commercial and regulatory activities of Phase 3 candidate ALZT-OP1 for early Alzheimer’s disease
The presentation will highlight AZTherapies’ lead Phase 3 clinical candidate and pipeline of candidates.
Jay Mohr, Chief Operating and Business Officer, will be providing a corporate update and participating on a late-stage CNS therapeutics panel.
The presentation will highlight AZTherapies’ lead Phase 3 clinical candidate and pipeline of candidates.